通过并购进入真菌检测和分子诊断领域。25H1 公司已经完成对控股子公司河北透景的整合工作，并将 助力河北透景加速真菌微生物检测产品研发、注册报批、临床推广工作的落地，河北透景主要聚焦于侵 袭性真菌病检测领域，通过本次并购，公司快速进入到侵袭性真菌病检测领域，填补了原有产品的空 白。 今年8 月，公司公告称拟推进并购康录生物，截至9 月29 日，本次并购2025年相关股份转让交割已全部 完成，康录生物是病理诊断细分领域的龙头企业，产品主要包括FISH 和PCR 两大类，本次并购有助于 公司开拓分子病理细分技术领域，形成"流式荧光+PCR+FISH"多维技术布局。 公司发布25 年中报，25H1 营业收入1.59 亿元（-26.25%），归母净利润0.03亿元（-58.41%），扣非净 利润-0.02 亿元（24 年同期为0.03 亿元）。25Q2，营业收入0.84 亿元（-31.35%），归母净利润0.02 亿 元（-79.43%），扣非净利润35 万元（-96.00%）。 评论： 试剂端承压于集采和高端肿瘤检测需求减少，仪器端装机顺利推进。试剂收入是公司的主要收入来源， 25H1 公司试剂收入1.47 亿元， ...

Core Viewpoint - The company TuoJing Life plans to acquire 82% of the shares of KangLu Bio for a total consideration of 328 million yuan, aiming to find new growth points after experiencing ten consecutive quarters of revenue decline due to IVD centralized procurement price reductions [1][4]. Group 1: Acquisition Details - The acquisition will occur in three phases, with an initial payment of approximately 29.15 million yuan for 72.863% of KangLu Bio's shares, making it a controlling subsidiary [1][3]. - The total valuation of KangLu Bio is set at 400 million yuan, with a premium rate of 226.53% over its book value [3]. - The acquisition will result in an estimated goodwill of about 277.5 million yuan for TuoJing Life [3]. Group 2: Financial Performance and Commitments - KangLu Bio has commitments to achieve net profits of no less than 22 million yuan, 31.5 million yuan, and 38 million yuan for the years 2025 to 2027, totaling at least 91.5 million yuan [3]. - The agreement includes provisions for performance compensation if actual profits fall below 80% of the promised figures [3]. - TuoJing Life's revenue has declined significantly, with Q1 2024 and Q1 2025 revenues reported at approximately 437 million yuan and 74.89 million yuan, respectively, both down by 19.53% year-on-year [4]. Group 3: Strategic Intentions - The company is actively seeking to expand its product portfolio through strategic investments and acquisitions, including non-centralized procurement fungal detection products [5][6]. - Future acquisition plans for remaining shares of KangLu Bio are contingent on meeting performance and receivables recovery commitments, with potential cash or share-based payments planned for 2028 to 2030 [4][6]. - The remaining shareholders of KangLu Bio include industry funds, indicating potential indirect benefits for companies like YangPu Medical and David Medical from this transaction [6].

公告显示，康录生物专注于荧光原位杂交(FISH)细分领域和PCR等分子诊断领域的拓展，致力于实现 FISH检测的快速化、自动化和智能化整体解决方案，目前已实现FISH试剂快速化，检测设备自动化的 研发生产和销售，拥有完全自主知识产权的FastProbe®快速荧光原位杂交探针制备技术。康录生物的产 品主要包括FISH和PCR两大类。本次交易在发展战略、市场渠道、产品与技术上均可获得协同效应。 同时，在首次交易完成后，康录生物将纳入公司合并报表范围内，预期将给公司带来新的收入及利润增 长点，提升公司整体竞争力。 本次收购康录生物72.8630%股份的交易金额为人民币2.91亿元;2026年及2027年，若满足本次交易有关 协议约定的前置条件，公司将进一步向陈刚和谢俊收购其所持康录生物9.1370%的股份，同样以上述资 产评估报告为定价参考依据，确定交易金额为3654.81万元。 智通财经APP讯，透景生命(300642.SZ)公告，公司拟先行收购武汉康录生物技术股份有限公司(简称"康 录生物")72.8630%的股份。在公司收购康录生物72.8630%股份完成后，康录生物将成为公司控股子公 司，纳入公司合并报表范 ...

Group 1 - The company plans to acquire 72.8630% of Wuhan Kanglu Biological Technology Co., Ltd. for a transaction amount of RMB 291 million, which will make Kanglu a subsidiary included in the company's consolidated financial statements [1] - Following the initial acquisition, the company intends to purchase an additional 9.1370% of Kanglu's shares in 2026 and 2027, contingent upon meeting certain preconditions, with a transaction amount of RMB 36.5481 million [1] - Upon completion of all transactions, the company will hold a total of 82.00% of Kanglu's shares [1] Group 2 - Kanglu focuses on the fluorescence in situ hybridization (FISH) and PCR molecular diagnostics fields, aiming for rapid, automated, and intelligent solutions in FISH detection [2] - The company has developed and commercialized rapid FISH reagents and automated detection equipment, possessing proprietary technology for FastProbe rapid FISH probe preparation [2] - The acquisition is expected to create synergies in strategic development, market channels, products, and technology, enhancing the company's overall competitiveness and providing new revenue and profit growth opportunities [2]